ArticleBMC pulmonary medicine2025
Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLung cancer (LC), the primary cause for cancer-related death globally is a diverse illness with various characteristics. Saliva is a readily available biofluid and a rich source of miRNA. It can be collected non-invasively as well as transported and stored easily. The process is also reproducible and cost-effective. The aim of this study was to evaluate the salivary expression of microRNAs let-7a-2, miR-221, and miR-20a in saliva and evaluate their efficacy, using multiple logistic regression (MLR) model, in diagnosis of lung cancer. MATERIALS: Samples of saliva were obtained from 40 lung cancer patients (20 lung adenocarcinoma and 20 lung squamous cell carcinoma) and 20 healthy controls. The levels of let-7a-2, miR-221, and miR-20a expression in saliva were assessed by RT-qPCR. Receiver operating characteristic (ROC) curve was utilized to assess the potential significance of miRNAs in saliva for lung cancer diagnosis with the use of multiple logistic regression (MLR), principal component analysis, and machine learning methods.
resultsDiagnostic odds ratio (DOR) of miR-20a in lung adenocarcinoma diagnosis versus healthy control was higher than miR-221, and DOR of miR-221 was higher than let-7a-2. miR-20a demonstrated a higher DOR for small cell lung carcinoma versus healthy control compared to let-7a-2, which in turn exhibited a higher DOR than miR-221. MLR of miR-221, let-7a-2, miR-20a, and smoking habit using main effects led to accuracy of 0.725 (sensitivity: 0.80, specificity: 0.65) and AUC = 0.795 for differentiation of small-cell lung carcinoma from lung adenocarcinoma. Our results showed that MLR based on salivary miRNAs could diagnose LUAD and SCLC from healthy control using main effects and two-way interactions with the accuracy of 0.90 (sensitivity = 0.95 and specificity = 0.85).
conclusionA salivary miRNA-based MLR model is a promising diagnostic tool for lung cancer, offering a non-invasive screening option for high-risk asymptomatic individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.